Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios

Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios

Bibliographic Details
Main Authors:	Carles Zafón, Beatriz Castelo
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	Cancer Medicine
Online Access:	https://doi.org/10.1002/cam4.5154

Similar Items

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
by: Miguel‐Ángel Berciano‐Guerrero
Published: (2022-10-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
by: S. Morelli, et al.
Published: (2017-07-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study
by: Chie Masaki, et al.
Published: (2022-12-01)

Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma
by: Chiara Paglino, et al.
Published: (2011-12-01)

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan
by: Sh. Kh. Gantsev, et al.
Published: (2020-11-01)

Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma
by: LIU Wei
Published: (2023-11-01)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
by: Nicola Bougen-Zhukov, et al.
Published: (2022-03-01)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
by: Swathi Veeroju, et al.
Published: (2021-02-01)

The Multikinase Inhibitor AD80 Induces Mitotic Catastrophe and Autophagy in Pancreatic Cancer Cells
by: Keli Lima, et al.
Published: (2023-07-01)

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
by: Iwona Karwaciak, et al.
Published: (2019-05-01)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
by: Kazuyuki Oishi, et al.
Published: (2017-05-01)

Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species
by: Blanca Cucarull, et al.
Published: (2021-08-01)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
by: Keisuke Enomoto, et al.
Published: (2021-02-01)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.
by: Yoshikazu Tateai, et al.
Published: (2023-01-01)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
by: Yoshikazu Tateai, et al.
Published: (2023-01-01)

Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer
by: Yuma Shibutani, et al.
Published: (2023-03-01)

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
by: Hao Jiang, et al.
Published: (2023-05-01)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
by: Songporn Oranratnachai, et al.
Published: (2023-02-01)

Specificity of hand-foot skin reaction induced by multikinase inhibitors: clinical, histological and ultrasound characteristics
by: E. A. Shatokhina, et al.
Published: (2020-07-01)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
by: João Roque, et al.
Published: (2023-04-01)

Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model
by: Kensuke Suzuki, et al.
Published: (2022-08-01)

Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges
by: Emanuele Rinninella, et al.
Published: (2020-10-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer
by: Silvia Cantara, et al.
Published: (2023-03-01)

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
by: Vineeth Sukrithan, et al.
Published: (2023-01-01)

Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib
by: Meihua Jin, et al.
Published: (2023-08-01)

Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
by: Soji Toda, et al.
Published: (2021-11-01)

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
by: M. E. Cabanillas, et al.
Published: (2020-02-01)

SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models
by: Xin Chen, et al.
Published: (2013-07-01)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
by: Javier Martínez‐Trufero
Published: (2022-10-01)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
by: Jaume Capdevila, et al.
Published: (2023-08-01)

Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis
by: Xianhua She, et al.
Published: (2024-03-01)

Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma
by: Ji Won Han, et al.
Published: (2023-04-01)

Association between baseline blood pressure and the incidence of lenvatinib‐induced hypertension in patients with thyroid cancer
by: Yuma Shibutani, et al.
Published: (2023-11-01)

Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
by: Carla Colombo, et al.
Published: (2023-06-01)